NEW YORK, March 18, 2023 (GLOBE NEWSWIRE) —

Seagen Inc. SGEN

Lifshitz Law PLLC announces an investigation into a possible breach of fiduciary duties in connection with the sale of SGEN to Pfizer Inc. for $229.00 per share in cash.

If you are an SGEN investor and would like additional information about our research, please fill out Information Request Form or contact Joshua Lifshitz, Esq. by phone at (516) 493-9780 or by email info@lifshitzlaw.com.

Provention Bio, Inc. PRVB

Lifshitz Law PLLC announces an investigation into a possible breach of fiduciary duties in connection with the sale of PRVB to Sanofi SA for $25.00 per share in cash.

If you are a PRVB investor and would like additional information about our research, please fill out Information Request Form or contact Joshua Lifshitz, Esq. by phone at (516) 493-9780 or by email info@lifshitzlaw.com.

Kimball International, Inc. KBAL

Lifshitz Law PLLC announces an investigation into a possible breach of fiduciary duties in connection with the sale of KBAL to HNI Corporation for $9.00 in cash and 0.3101 HNI common shares for each Kimball common share.

If you are a KBAL investor and would like more information about our research, please fill out Information Request Form or contact Joshua Lifshitz, Esq. by phone at (516) 493-9780 or by email info@lifshitzlaw.com.

Adaptimmune Therapeutics PLC ADAP

Lifschitz LAwPLC Announces Investigation into a Possible Breach of Fiduciary Duty in Connection with the ADAP/TCR² Therapeutics, Inc. Merger. Post-merger, pre-merger Adaptimmune shareholders are expected to own approximately 75.0% of the combined company’s outstanding equity.

If you are an ADAP investor and would like additional information about our research, please fill out Information Request Form or contact Joshua Lifshitz, Esq. by phone at (516) 493-9780 or by email info@lifshitzlaw.com.

LAWYER ADVERTISING.© 2023 Lifschitz Law PLLC….